Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John W Frew

Showing results (71-80 of 91) with videos related to

Pageof 10
Sort By:
Dermatology (Basel, Switzerland)|November 14, 2023
Infectious Disease Screening prior to Systemic Immunomodulatory Therapy in Hidradenitis Suppurativa: Consensus Guidelines from the Asia-Pacific Hidradenitis Suppurativa FoundationEmily K Kozera, Martina Porter, So Yeon Paek, et al.
Journal of Clinical and Translational Science|May 21, 2025
Full spectrum town halls for hidradenitis suppurativa: A model for advancing clinician-patient-researcher engagement in clinical and translational researchAnuradha Hashemi-Arend, Michelle A Lowes, John W Frew, et al.
Skin Appendage Disorders|August 18, 2022
Guidance on COVID-19 Vaccination in Hidradenitis Suppurativa Patients: A Modified Delphi Consensus of ExpertsJonathan W Rick, Devea R De, Terri Shih, et al.
JAMA Dermatology|March 10, 2021
Global Harmonization of Morphological Definitions in Hidradenitis Suppurativa for a Proposed GlossaryJohn W Frew, Michelle Anne Lowes, Noah Goldfarb, et al.
The British Journal of Dermatology|May 23, 2022
The road to biologics in patients with hidradenitis suppurativa: a nationwide drug utilization studyHans Christian Ring, Yiqiu Yao, Julia-Tatjana Maul, et al.
The British Journal of Dermatology|April 5, 2024
Proof-of-concept study exploring the effect of spesolimab in patients with moderate-to-severe hidradenitis suppurativa: a randomized double-blind placebo-controlled clinical trialAfsaneh Alavi, Errol P Prens, Alexa B Kimball, et al.
Experimental Dermatology|June 4, 2021
Target molecules for future hidradenitis suppurativa treatmentChristos C Zouboulis, John W Frew, Evangelos J Giamarellos-Bourboulis, et al.
American Journal of Clinical Dermatology|March 10, 2026
Defining Moderate Disease and Progression in Hidradenitis Suppurativa: An Expert Framework to Unlock the Window of Opportunity for Prompt TreatmentAntonio Martorell, John R Ingram, Christopher J Sayed, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|April 10, 2024
Discrepancies in hidradenitis suppurativa lesion characterization by providers and patientsLindsey Greenlund, Claire Herzog, Zachary Wendland, et al.
Journal of the American Academy of Dermatology|October 1, 2013
A phase II randomized vehicle-controlled trial of intradermal allogeneic fibroblasts for recessive dystrophic epidermolysis bullosaSupriya S Venugopal, Wenfei Yan, John W Frew, et al.
Pageof 10

Showing results (71-80 of 91) with videos related to

Sort By:
Pageof 10
Dermatology (Basel, Switzerland)|November 14, 2023
Infectious Disease Screening prior to Systemic Immunomodulatory Therapy in Hidradenitis Suppurativa: Consensus Guidelines from the Asia-Pacific Hidradenitis Suppurativa FoundationEmily K Kozera, Martina Porter, So Yeon Paek, et al.
Journal of Clinical and Translational Science|May 21, 2025
Full spectrum town halls for hidradenitis suppurativa: A model for advancing clinician-patient-researcher engagement in clinical and translational researchAnuradha Hashemi-Arend, Michelle A Lowes, John W Frew, et al.
Skin Appendage Disorders|August 18, 2022
Guidance on COVID-19 Vaccination in Hidradenitis Suppurativa Patients: A Modified Delphi Consensus of ExpertsJonathan W Rick, Devea R De, Terri Shih, et al.
JAMA Dermatology|March 10, 2021
Global Harmonization of Morphological Definitions in Hidradenitis Suppurativa for a Proposed GlossaryJohn W Frew, Michelle Anne Lowes, Noah Goldfarb, et al.
The British Journal of Dermatology|May 23, 2022
The road to biologics in patients with hidradenitis suppurativa: a nationwide drug utilization studyHans Christian Ring, Yiqiu Yao, Julia-Tatjana Maul, et al.
The British Journal of Dermatology|April 5, 2024
Proof-of-concept study exploring the effect of spesolimab in patients with moderate-to-severe hidradenitis suppurativa: a randomized double-blind placebo-controlled clinical trialAfsaneh Alavi, Errol P Prens, Alexa B Kimball, et al.
Experimental Dermatology|June 4, 2021
Target molecules for future hidradenitis suppurativa treatmentChristos C Zouboulis, John W Frew, Evangelos J Giamarellos-Bourboulis, et al.
American Journal of Clinical Dermatology|March 10, 2026
Defining Moderate Disease and Progression in Hidradenitis Suppurativa: An Expert Framework to Unlock the Window of Opportunity for Prompt TreatmentAntonio Martorell, John R Ingram, Christopher J Sayed, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|April 10, 2024
Discrepancies in hidradenitis suppurativa lesion characterization by providers and patientsLindsey Greenlund, Claire Herzog, Zachary Wendland, et al.
Journal of the American Academy of Dermatology|October 1, 2013
A phase II randomized vehicle-controlled trial of intradermal allogeneic fibroblasts for recessive dystrophic epidermolysis bullosaSupriya S Venugopal, Wenfei Yan, John W Frew, et al.
Pageof 10